Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection

Armando Santoro, MD

Status: Completed

Conditions: NON-SMALL-CELL LUNG CANCER

Study type: Observational

Funder types: Other

Identifiers

NCT00831454

ONC/OSS-02/2008

Details and patient eligibility

About

The aim of this study was to retrospectively evaluate associations between EGFR and AKT DNA-polymorphisms involved in transcriptional regulation and overall survival in NSCLC patients treated with EGFR-TKIs.

Full description

DNA will be isolated from blood samples or paraffin-embedded tumor specimens and than a mutation analysis and SNPs genotyping will be done.

Enrollment: 51 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Availability of tumor tissue or blood samples.
• Diagnosis of NSCLC
• At least one treatment with EGFR-TKIs inhibitors

Exclusion criteria

• Other than NSCLC primary diagnosis
• No treatment with EGFR-TKIs inhibitors
• No archival tissue available